The Role of Antipsychotics in the Management of Fibromyalgia (Q37980516)

26 August 2017

title

The role of antipsychotics in the management of fibromyalgia (English)

1 reference

26 August 2017

The Role of Antipsychotics in the Management of Fibromyalgia (English)

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

24 December 2024

0 references

Elena P Calandre

1

0 references

Fernando Rico-Villademoros

object named as

Fernando Rico-Villademoros

series ordinal

2

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22296316

24 December 2024

publication date

1 February 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

26

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

135-153

1 reference

History of fibromyalgia: past to present

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Improving the Recognition and Diagnosis of Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The relationship of alpha and delta EEG frequencies to pain and mood in ‘fibrositis’ patients treated with chlorpromazine and l-tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Trazodone for the treatment of fibromyalgia: an open-label, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Treatment of fatigue in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Fibromyalgia and fatigue: central processing, widespread dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The prevalence and characteristics of fibromyalgia in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Prevalence of the major rheumatic disorders in the adult population of north Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Prevalence of fibromyalgia: a survey in five European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Prevalence of Musculoskeletal Pain and Rheumatic Diseases in the Southeastern Region of Mexico. A COPCORD-Based Community Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Neuroendocrine immunology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Autonomic dysfunction in fibromyalgia syndrome: postural orthostatic tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

An elephant among us: the role of dopamine in the pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Etiology of fibromyalgia: the possible role of infection and vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

An Evolutionary Stress-Response Hypothesis for Chronic Widespread Pain (Fibromyalgia Syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Fibromyalgia: from pathophysiology to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Chronic conditions and health problems in rheumatic diseases: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, systemic lupus erythematosus, and fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

An internet survey of 2,596 people with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A cluster within the continuum of biopsychosocial distress can be labeled "fibromyalgia syndrome"--evidence from a representative German population survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Fibromyalgia Syndrome: A Discussion of the Syndrome and Pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Cognitive behavioral therapy for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Are psychological treatments effective for fibromyalgia pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Psychological treatments for fibromyalgia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Efficacy of acupuncture in fibromyalgia syndrome--a systematic review with a meta-analysis of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Evidence for the efficacy of complementary and alternative medicines in the management of fibromyalgia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

EULAR evidence-based recommendations for the management of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Antidepressants for the treatment of chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Milnacipran: in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: Results from a 14-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Sodium oxybate for the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The natural history of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

A six year prospective study of a cohort of patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Prospective epidemiological observations on the course of the disease in fibromyalgia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Involvement of calmodulin inhibition in analgesia induced with low doses of intrathecal trifluoperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Prochlorperazine induces central antinociception mediated by the muscarinic system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The antipsychotic drug, fluphenazine, effectively reverses mechanical allodynia in rat models of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Phenothiazine-type antipsychotics elicit cutaneous analgesia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Enhancement of morphine analgesia after acute and chronic haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The neuroleptics as adjuvant analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Management of migraine headache in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Antipsychotics for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Anxiety and depressive symptoms in fibromyalgia are related to poor perception of health but not to pain sensitivity or cerebral processing of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Review of atypical antipsychotics in anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Utility of atypical antipsychotics in the treatment of resistant unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Levomepromazine helps to reduce sleep problems in patients with PTSD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Allelic variation in the 5-HT2C receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Effect of a single-dose of olanzapine on sleep in healthy females and males

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Olanzapine for the treatment of fibromyalgia symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

An open-label study of quetiapine in the treatment of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Use of ziprasidone in patients with fibromyalgia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Sleep-promoting properties of quetiapine in healthy subjects

21 January 2018

1 reference

12 December 2020

Analgesic effects of tiapride in man. A double-blind comparative clinical trial against placebo (author's transl)

1 reference

12 December 2020

The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario

1 reference

12 December 2020

The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome.

1 reference

12 December 2020

Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis

1 reference

12 December 2020

A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome

1 reference

12 December 2020

Treatment of fibromyalgia with tropisetron--dose and efficacy correlations

1 reference

12 December 2020

Course of the Manic-Depressive Cycle and Changes Caused by Treatments

1 reference

12 December 2020

An open-label study of levopromazine (methotrimeprazine) as an add-on therapy in fibromyalgia management.

1 reference

12 December 2020

Typical and atypical antipsychotics in bipolar depression.

1 reference

12 December 2020

The Atypical Neuroleptics Clozapine and Olanzapine Differ Regarding Their Antinociceptive Mechanisms and Potency

1 reference

12 December 2020

New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey

1 reference

12 December 2020

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review

1 reference

12 December 2020

Pathophysiology of fibromyalgia

1 reference

12 December 2020

Second-generation antipsychotics for major depressive disorder and dysthymia

1 reference

12 December 2020

Chlorpromazine hyperalgesia antagonizes clonidine analgesia, but enhances morphine analgesia in rats tested in a hot-water tail-flick paradigm

1 reference

12 December 2020

WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran.

1 reference

12 December 2020

Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety?

1 reference

12 December 2020

Prevalence of rheumatic diseases and associated outcomes in rural and urban communities in Bangladesh: a COPCORD study

1 reference

12 December 2020

Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study

1 reference

12 December 2020

Health status and disease severity in fibromyalgia. Results of a six-center longitudinal study

1 reference

12 December 2020

Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects.

1 reference

12 December 2020

Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach

1 reference

12 December 2020

Effect of fluphenazine on the footshock-induced opioid analgesia and leu-enkephalin concentration in the rat brain.

1 reference

12 December 2020

A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.

1 reference

12 December 2020

Characterization of analgesic and activity effects of methotrimeprazine and morphine

1 reference

12 December 2020

A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia

1 reference

12 December 2020

Antipsychotics for acute and chronic pain in adults

1 reference

12 December 2020

Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?

1 reference

12 December 2020

Efficacy of tramadol in treatment of pain in fibromyalgia.

1 reference

12 December 2020

Low doses of risperidone and morphine interact to produce more analgesia and greater extrapyramidal effects in rats

1 reference

12 December 2020

Epidemiologic study of soft tissue rheumatism in Shantou and Taiyuan, China

1 reference

12 December 2020

The Journal of Rheumatology

18

26

1570

White

July 1999

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Clinical and Immunomodulatory Effect of Fun-boi, an Herbal Medicine, in Rheumatoid Arthritis.

24 December 2024

series ordinal

66

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Research Communications in Chemical Pathology and Pharmacology

24 December 2024

74

26

25

St John

October 1979

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

Polish journal of pharmacology and pharmacy

24 December 2024

87

40

621

Kowalski

November 1988

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

24 December 2024

94

40

1

Bogetto

1999

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris

24 December 2024

95

56

430

Clavel

March 1980

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

24 December 2024

116

174

421

Cohrs

July 2004

1 reference

https://api.crossref.org/works/10.2165/11597130-000000000-00000

24 December 2024

Identifiers

1 reference

Dimensions Publication ID

26 August 2017

1052729620

0 references

1 reference